Video in regulated markets: what medtech and fintech can and cannot claim
The most expensive stage to discover a compliance problem is the final cut.
The most expensive stage to discover a compliance problem is the final cut. Voiceover has been recorded, the edit is locked, the music is timed to the picture. Then a regulatory reviewer flags one sentence, and fixing it means re-recording, re-editing, and moving your launch by a month.
I have watched this happen. It is avoidable, and avoiding it is a scripting problem rather than a legal one.
Why this catches people out
Most video studios have never worked in a regulated market. They write copy the way copy gets written everywhere else, using comparatives and superlatives and outcome claims, because in most sectors that language is unremarkable.
Then it reaches a medical device manufacturer's regulatory function, and half of it cannot be said.
The problem is not that the studio was careless. The problem is that the constraints were never in the brief, because the client assumed a video agency would know, and the agency assumed the client would review at the end.
What actually constrains you: medical devices in the EU
Under the Medical Device Regulation, promotional material for a device cannot claim performance the device is not certified for. This sounds obvious and gets violated constantly in subtle ways.
Indication drift. Your device is certified for one clinical use. The film shows it in a scene implying a broader one. Nobody said anything false. The visual made a claim the certification does not support.
Comparative claims. "More accurate than conventional methods" requires evidence you can produce on request. A clinician saying it on camera does not make it their opinion rather than your claim, because you edited and published it.
Outcome language. Words like "safe," "effective," "painless" and "guaranteed" carry specific regulatory weight. They are not adjectives in this context.
Patient testimony. Rules vary by member state and Slovenia is stricter than several neighbours. In some jurisdictions a patient describing their own outcome constitutes a performance claim by you.
Off-label depiction. Showing a device used in a way outside its intended purpose is a violation even if the voiceover says nothing about it. If it appears on screen, you claimed it.
There is also a national layer. Slovenian healthcare advertising law places restrictions on how medical services can be promoted to the public that go beyond the EU baseline, and these apply to a private clinic's own film about itself. Croatia and Austria differ again. A film intended for three markets needs to clear the strictest of the three or exist in three versions.
Financial services
Different regulator, similar structure.
Anything that could be read as investment advice pulls in a separate set of obligations. Performance figures generally require risk disclosure, and a disclaimer in eight-point type at the end of a film does not meet the standard in most interpretations. If you are regulated in one EU market and the film runs in another, both regimes may apply.
The recurring error is treating disclosure as something bolted on at the end. If the claim needs a qualification, the qualification has to be as prominent as the claim, which means it has to be in the script.
How to build the constraint in
Three changes to the normal process. They cost almost nothing at the start and save weeks later.
Get the constraints before the script, not after. One meeting with whoever owns regulatory review at your company, before writing begins. Two questions: what can we not say, and what can we not show. Written down, in the brief.
Script review, not cut review. Regulatory sees the script at the point where changing a sentence costs one email. If review happens for the first time at the final cut, every change is expensive and some are impossible without a reshoot.
Log every claim. A simple table: the claim, where it appears, and the evidence supporting it. Regulatory reviewers are far quicker to approve when they can see the reasoning. This also protects you later, because if a claim is challenged in two years you have the record.
What you can still do
This section matters more than the constraints, because the usual reaction to a regulatory briefing is to make something so cautious it says nothing.
Show the process rather than claiming the outcome. You cannot say the procedure is painless. You can show it, at real speed, with the clinician explaining what they are doing. The viewer draws their own conclusion, which is more persuasive anyway.
Let the constraint be the story. For a medical device company, the certification process is genuinely hard and genuinely differentiating. Most companies treat it as a compliance burden to be mentioned in passing. It is evidence of rigour, and competitors who cut corners cannot show it.
Address the buyer who is not the patient. Hospital procurement, clinical directors, distributors. These audiences sit outside most consumer-facing advertising restrictions and they are the ones actually purchasing. A film for a procurement committee has substantially more room than a film for the public.
Use the engineering. Manufacturing tolerance, materials, testing, the failure modes you designed against. None of this is a clinical claim, all of it builds credibility with the technical members of a buying committee, and almost nobody films it.
The cost of getting it wrong
Beyond the rework, there is real regulatory exposure. National competent authorities can require withdrawal of promotional material, and in serious cases the penalties reach into the tens of thousands of euros. For a device company, a compliance finding in promotional material also becomes a data point in your relationship with the regulator, which is not a relationship you want to complicate.
Weighed against one meeting before scripting begins, it is not a close call.
FAQ
Does this apply to internal or trade-only videos? Trade-only material has more latitude in most jurisdictions than material aimed at the public or patients, but it is not unregulated, and "trade-only" is difficult to maintain once something is on a website or LinkedIn. Assume anything published is public.
Can a doctor make claims on camera that we cannot make ourselves? Generally no. Once you commission, edit and publish the material, the claim is attributable to you. Independent clinical opinion published independently is a different situation from a clinician speaking in your promotional film.
Do these rules apply to a private clinic advertising its own services? Yes, and in Slovenia the restrictions on advertising healthcare services to the public are stricter than many people expect. This is separate from device regulation and catches clinics that assumed device rules did not apply to them.
How much time should we budget for regulatory review? Two to four weeks in medtech for a film of any substance, split across script and final cut. This is not compressible by asking nicely, and building it into the timeline from the start prevents it from consuming your launch date.
Should we hire a lawyer to review the film? For most projects, your internal regulatory function is enough if they are involved early. External legal review is worth it for a first film in a new market, for anything making comparative claims, and for material running across multiple jurisdictions with different rules.